Remegen is a biotech company focused on discovering and developing a new generation of targeted therapies for the treatments of cancer.
RemeGen, Ltd. ("RemeGen") is a biopharmaceutical company in China dedicated to fulfilling unmet medical needs for patients with life-threatening conditions. RemeGen's main focus is research and development, manufacturing and commercialization of novel biologics, most notably monoclonal antibodies (mAb) and antibody-drug conjugates (ADCs). Headquartered in Yantai, Shandong Province, China, RemeGen has labs/offices in Beijing and California.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Mar 17, 2020 | Private Equity(PE) | $100M | 1 | Lilly Asia Ventures | — | Detail |
Dec 7, 2019 | Private Equity(PE) | — | 2 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Lilly Asia Ventures | Yes | Private Equity(PE) |
Huatai Health Fund | — | Private Equity(PE) |
Mingxin China Growth Fund | — | Private Equity(PE) |